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ABSTRACT
Background: Allergen-specific immunotherapy (SIT) is currently used for several allergic disorders and IL-10-
producing regulatory T cells (Tr1) induced by SIT suppress allergic reactions. We investigated the relation be-
tween IL-10 production and acquiring allergy.
Methods: A prospective study was undertaken to evaluate the effect of SIT on IL-10 production in T cells and
other cell fractions in children with pollinosis. In addition, blood samples were collected from non-allergic
healthy controls and patients with pollinosis to compare the levels of IL-10 production. PBMC were cultured
with pollen peptides or control allergens, and the IL-10 production from monocyte and CD4 T cell was ana-
lyzed.
Results: Monocytes and CD4 T cells from SIT group of patients produced high levels of IL-10, suggesting that
the induction of IL-10 is essential for inducing T cell tolerance. IL-10 production from monocytes and T cells
was significantly increased in non-allergic controls compared to patients with pollinosis. This high IL-10 produc-
tion was observed even when PBMC were stimulated with antigens other than pollen peptides.
Conclusions: IL-10 is critical for induction of specific T cell tolerance, and increased production of IL-10 by
monocytes and T cells during inflammatory responses or after SIT may influence effector cells in allergy. Pre-
sent data implicates that the low productivity of IL-10 by monocytes and T cells is closely related with sensitivity
to multiple allergens, and resistance to allergic diseases. Augmentation of constitutive IL-10 production from
immune system is a potential therapeutic approach for allergic disorders.
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ABBREVIATIONS
SIT, allergen-specific immunotherapy; Tr1, IL-10 producing regulatory T cell; SLIT, sublingual allergen-specific
immunotherapy; PBMC, peripheral blood mononuclear cells; nTregs, naturally occurring regulatory T cells;
CFSE, 5 (and 6)-carboxyfluorescein diacetate, succinimidyl ester; SMS, symptom medication score; TNSS, to-
tal nasal symptom score.
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INTRODUCTION
IL-10 is a regulatory cytokine secreted during inflam-
matory responses where they inhibit T cell prolifera-
tion. IL-10 plays a pivotal role in the acquisition and
maintenance of specific T cell tolerance.1 IL-10 is pro-
duced by a variety of cells including monocytes
macrophages, T cells (Th1, Th2, Th17),2,3 B cells,4
and mast cells.5,6 Peptide-based allergen-specific im-
munotherapy (SIT) is currently being used for the
treatment of several allergic diseases. IL-10-
producing regulatory T cells (Tr1) induced by SIT
suppress allergic reactions.7-9 Immunotherapy for
Japanese cedar pollinosis is performed by sublingual
application of a pool of pollen peptides containing Cry
j1 and Cry j2, which are the major Japanese cedar pol-
len allergens, and its clinical efficacy on seasonal al-
lergic rhinitis has been previously appraised.10-12 Sub-
lingual allergen-specific immunotherapy (SLIT) is
very suitable to children with allergy because it is
safe (eg, no risk of anaphylaxis) and its administra-
tion is not painful. Allergen-specific regulatory T cells
play important roles in the mechanism of immunopro-
tection.7,13-15 We have recently demonstrated that one
of the mechanism of the beneficial effect of SLIT de-
pends on its ability to increase the number of circulat-
ing Tr1 (IL-10+CD4+ T cell).9 The increased Tr1
population in SLIT-received patients functionally sup-
presses T cell proliferation when stimulated by pollen
peptides compared to that from pollen allergy pa-
tients, and this suppressive effect was neutralized by
the addition of anti IL-10 antibody or anti-IL-10 recep-
tor antibody, confirming that the suppression of reac-
tivity against cedar pollen in SLIT-received patients is
IL-10-dependent9; however, whether its effect is time-
dependent remains still unclear. In the present study,
we performed a prospective SLIT in children with pol-
linosis, to compare the percentage of Tr1 cells and
other cell fractions between pre-treatment, during-
treatment, and post-treatment. In addition, to evaluate
whether low IL-10 production is associated with de-
velopment of allergic disease, the level of IL-10 pro-
duction was compared between patients with allergy
to Japanese cedar pollen and non-allergic healthy con-
trols. We discussed the possible mechanism of be-
coming sensitive to multiple allergens.
METHODS
PATIENTS AND SLIT PROTOCOL
This prospective study comprised 46 children (age,
14.1 ± 7.7 years; malefemale, 3511) sensitive to
Japanese cedar referred to the Department of Otorhi-
nolaryngology of Mie University Hospital. Diagnosis
was based on clinical symptoms and serological re-
sults. Blood was drawn after obtaining written in-
formed consent from all subjects and the investiga-
tional protocol was approved by the Institutional Re-
view Board (IRB) of Mie University Hospital. The
protocol details of SLIT are described previously.12 In
brief, the allergen administration was every day from
beginning to the forth week. On the first week, 2 JAU
of allergen was administered from 1 drop to 10 drops,
on the second week, 20 JAU of allergen was adminis-
tered from 1 drop to 10 drops, on the third week, 200
JAU of allergen was administered from 1 drop to 10
drops, and then on forth week 2000 JAU of allergen
was administered from 1 drop to 20 drops, as the final
dose. On the fifth week twice a week, after the sixth
week, 2000 JAUml was administered to sublingual
20 drops as the final highest dose by once a week.
Blood samples were collected pre- (November to De-
cember), during- (at the fifth week, January), and
after-completing SIT (February).
In other experiments, fresh blood was also col-
lected from 21 adult non-allergic healthy volunteers
(age, 31.1 ± 5.7 years; malefemale, 147) and 25
adult patients (age, 33.1 ± 7.1 years; malefemale, 20
5) with allergy to Japanese cedar pollen. This proto-
col was also approved by IRB.
PBMC CULTURE
Peripheral blood mononuclear cells (PBMC) were
isolated from 20 mL of heparinized venous blood by
density gradient centrifugation using Ficoll (Sigma,
St. Louis, MO, USA). PBMC were cultured in RPMI
1640 medium (Nikken Bio Medical Laboratory,
Kyoto, Japan) containing L-glutamine supplemented
with 100 UmL penicillin, 100 UmL streptomycin
(Invitrogen, Carlsbad, CA, USA), and 10% Human AB
serum (Gemini Bio-Products, West Sacramento, CA,
USA). The cells were plated on 24-well tissue culture
plates at a density of 2 × 106 cells1 mLwell and
were incubated with 50 IU of Cry j1 and Cry j2 (Torii,
Tokyo, Japan) for 8 h at 37℃ in an atmosphere of 5%
CO2. In a different experiment, PBMC were stimu-
lated with 1 μgmL of tetanus toxoid (Kaketsuken,
Kumamoto, Japan) or 250 ngml of PPD derived from
Mycobacterium Bovis (Japan BCG, Tokyo, Japan) as
control antigens. Endotoxin level was approved to be
less than 0.1 ngμg (1 EUμg) of the protein in Cry j1
and Cry j2, tetanus toxoid, and PPD.
STAINING OF NATURALLY OCCURRING REGU-
LATORY T CELLS (nTregs)
For identification of nTreg (FoxP3+CD25highCD4+ T
cells), freshly isolated PBMC were directly stained
with monoclonal antibodies to CD4-FITC and CD25-
PE in cell surface staining buffer containing 0.1 M
PBS and 2% FCS (Biowest, Nuaillé, France). Then, in-
tracellular staining with Foxp3-PECy5 antibody was
performed according to the manufacturer’s instruc-
tion (eBioscience, San Diego, CA, USA). The popula-
tion of nTregs was analyzed using a Becton Dickin-
son FACScan instrument (Becton Dickinson, Mans-
field, MA, USA).
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Fig.　1　a, Naturally occurring regulatory T cells (nTregs). The percentage of FoxP3+CD25highCD4+ T cells/ 
CD4+ T cells (nTreg) was unchanged during SLIT in patients with pollinosis. b, Proliferation assay. The 
proliferation was signifi cantly suppressed with the addition of Tr1, and this suppressive effect was neutral-
ized by the addition of 2 μg/mL of anti IL-10 antibody, confi rming that categorized Tr1 has the suppressive 
function. c, The percentage of IL-10-producing T cells, B cells, and monocytes in children undergoing SLIT. 
The percentage of circulating IL-10 producing monocytes was signifi cantly increased during and after SLIT 
compared to pre-treatment values. The percentage of circulating Tr1 cells was signifi cantly increased after 
the completion of SLIT. The number of IL-10 producing CD8+ T cells and B cells remained unchanged dur-
ing SLIT.
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PROLIFERATION ASSAY
In order to confirm that IL-10 producing T cells de-
fined Tr1 is truly functional or not, the proliferation
assay was performed. 2 × 106mL of PBMC were cul-
tured with 50 IU of Cry j1 and Cry j2 as mentioned
above. On the day 2, PBMC were collected and
washed, and then Tr1 was purified with using CD4 T
cell isolation kit II followed by IL-10 secretion assay
cell enrichment and detection kit (Miltenyi Biotec,
Auburn, CA, USA). CD4+IL-10-T cells were catego-
rized as non-Tr1. Simultaneously fresh PBMC were
collected from the same donor on the day 2, and then
CD4 T cells were purified in the same way. Collected
CD4 T cells were labeled with 10 μM of 5 (and 6)-
carboxyfluorescein diacetate, succinimidyl ester
(CFSE, Eugene, OR, USA) and then 2 × 104200 μL of
CFSE-stained CD4 T cells were stimulated by 10 IU
of Cry j1 and Cry j2 in the presence of 2 × 104 of non-
Tr1 cells, with or without 2 × 104 of Tr1 and 2 μgmL
of anti-IL-10 antibody in 96-well culture plate. After 4
days culture, cells were collected and cell prolifera-
tion was analyzed by Becton Dickinson FACScan in-
strument. The percentage of proliferative cells was
calculated (n = 6 per each population).
STAINING OF IL-10 IN T CELLS, B CELLS, AND
MONOCYTES
After 8 h culture with antigens, PBMC were collected
and incubated with PE-conjugated IL-10 secretion as-
say kit according to the manufacturer’s instructions
(Miltenyi Biotec). Cells were also co-stained with
anti-CD4-FITC and anti-CD19 PECy5 antibody, or
anti-CD14-FITC (eBioscience, San Diego, CA, USA)
and anti-CD8-PerCp antibody (Becton Dickinson,
Franklin Lakes, NJ, USA). The percentage of IL-10
producing CD4+T cells, CD8+T cells, B cells, and
monocytes were analyzed by flow cytometry.
EFFICACY OF SLIT AND THE PERCENTAGE OF
Tr1 OR IL-10 PRODUCING MONOCYTES
In order to investigate the correlation between the ef-
ficacy of SLIT and the percentage of Tr1 and IL-10
producing monocytes, symptom medication score
(SMS) and total nasal symptom score (TNSS) were
employed in children’s SLIT cases. Nasal and ocular
symptoms and medication(s) prescribed were classi-
fied from score 0 to 4 and score 0 to 3, respectively.
The sum of these scores was used as the symptom-
medication score (SMS). On the other hand, nasal
symptoms of sneezing, nasal discharge, and nasal
congestion were recorded each day. Symptoms were
categorized on a 5-point scale (0: none, 1: mild, 2:
moderate, 3: severe, 4: extremely severe) according
to Practical Guideline for the Management of Allergic
Rhinitis in Japan.11 The average of TNSS for the three
nasal symptom items in the cedar pollen season of
February and March 2008 was calculated.
STATISTICAL ANALYSIS
Statistical analysis was performed using the Kruskal-
Wallis nonparametric ANOVA and Dunn’s multiple
comparison test for post hoc analysis. A p value of less
than 0.05 was considered as statistically significant.
The relation between SMS or TNSS and the percent-
age of Tr1 or IL-10 producing monocytes was ana-
lyzed by relative correlation test.
RESULTS
NATURALLY OCCURRING REGULATORY T
CELLS (nTregs)
The percentage of nTreg (FoxP3+CD25highCD4+ T
cellsCD4+ T cells) remained unchanged during SLIT
in patients with pollinosis (Fig. 1a).
PROLIFERATION ASSAY
The percentage of CD4+lymphocytes proliferation
was measured and found that the proliferation was
significantly suppressed when Tr1 was supplemented
in the culture, and this suppressive effect was neutral-
ized by the addition of 2 μgmL of anti IL-10 antibody,
confirming that IL-10 producing CD4 T cells catego-
rized as Tr1 has the inhibitory function (Fig. 1b).
IL-10 PRODUCTION IN T CELL, B CELLS, AND
MONOCYTES DURING SLIT
The percentage of circulating IL-10 producing mono-
cyte (IL-10+CD14+ monocytesCD14+ monocytes)
was significantly increased during and after SLIT
compared to pre-treatment values. The percentage of
circulating Tr1 (IL-10+CD4+ T cellsCD4+ T cells)
cells was significantly increased after SLIT. However,
the number of IL-10 producing CD8+ T cells and B
cells remained unchanged during the course of SLIT
(Fig. 1c).
CORRELATION BETWEEN THE EFFICACY OF
SLIT AND THE PERCENTAGE OF Tr1 OR IL-10
PRODUCING MONOCYTES
The correlation between SMS or TNSS and the per-
centage of Tr1 or IL-10 producing monocytes did not
reach the significance (Fig. 2).
IL-10 PRODUCTION ANTIGEN STIMULATION IN
SUBJECTS WITH ANDWITHOUT ALLERGY
The percentage of both IL-10+CD14+monocyte
CD14+ monocytes and IL-10+CD4+ T cellCD4+ T
cells was significantly increased in PBMC from nor-
mal controls compared to patients with pollinosis
when they were stimulated with Cry j1 and Cry j2.
These significant elevations in the IL-10 producing
cell population were also observed when PBMC were
stimulated with tetanus toxoid or PPD (Fig. 3).
DISCUSSION
Here, we showed that monocytes and CD4+ T cells
from patients with good response to SLIT produce
Low Production of IL-10 Causes Allergy
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Fig.　2　Correlation between the efficacy of SLIT and the percentage of Tr1 and IL-10 pro-
ducing monocytes. In order to analyze the efficacy of SLIT, SMS and TNSS were employed 
for children’s SLIT cases. The correlation between SMS or TNSS and the percentage of Tr1 
or IL-10 producing monocytes did not reach the signifi cance.
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high levels of IL-10; suggesting that production of IL-
10 is essential for inducing T cell tolerance. In addi-
tion, we also discovered that IL-10 production by
monocytes and T cells is significantly decreased in
patients with Japanese cedar pollen allergy compared
to non-allergic healthy controls. This low IL-10 pro-
duction was observed even when PBMC were stimu-
lated with antigens other than cedar pollen peptides.
These observations suggest that low productivity of
IL-10 may be critical for becoming sensitive to multi-
ple allergens and for contracting allergic diseases.
In the first experiment, the percentage of circulat-
ing Tr1 (IL-10+CD4+ T cellCD4+ T cell) cells was
evaluated and found that it was significantly in-
creased in patients after SLIT. The categorized Tr1
was proved to have functionally suppressive ability;
which was neutralized with the addition of anti-IL-10
antibody. This increase in the Tr1 population may
naturally be the result of clonally expanded antigen
specific T cells. However, Tr1 cells can be generated
in the presence of IL-10 locally released from Tr1
cells,15 and it is known that the mechanism of cell
proliferation inhibition by Tr1 cells is cytokine-
mediated but not via cell-to-cell contact. We have pre-
viously shown that Tr1 cells with high production of
IL-10 induced by SLIT conserve high T cell repertoire
diversity without showing monoclonal expansion.9
This observation suggests that, SLIT causes toler-
ance to multiple allergens by inducing Tr1 cells with
high production of IL-10. Specific immunotherapy
blocks allergen-specific IgE and induces an allergen-
specific IgG response, which is stimulated by IL-10
Yamanaka K et al.
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Fig.　3　The percentage of IL-10-producing monocytes and T cells in healthy control and 
patients with pollinosis. PBMC from 21 healthy volunteers (N) and 25 patients with Japa-
nese cedar pollen allergy (A) were cultured with Cry j1 and Cry j2 (Cry), tetanus toxoid (TT), 
or PPD. The percentages of IL-10 producing monocytes and CD4 T cells were signifi cantly 
increased in PBMC from normal healthy individuals compared to those from patients with 
pollinosis, even when PBMC were stimulated with Cry j1 and Cry j2, tetanus toxoid, or PPD.
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from Tr1 cells.14 Another surprising finding is the in-
duction of monocyte population with high IL-10 pro-
duction ability by SLIT. The mechanism of this effect
is not clear but function of monocytes is probably
controllable by immunotherapy. Monocytes recog-
nize antigens via Toll like receptors, digest antigen
with intrinsic enzyme, and some monocyte popula-
tion such as CD14+CD16+ monocyte presents anti-
gens combined with its expressing MHC class II like
antigen presenting cells.16 During this process, IL-10
production may be increased. The relative percent-
age of IL-10 positive fraction is higher in monocytes
than in the Tr1 population, suggesting monocytes as
potential therapeutic target of allergic disorders. Con-
sidering that the percentage of Tr1 and IL-10 produc-
ing monocytes population is correlated to clinical
symptom or not can be answered with using SMS
and TNSS scores. As shown in Figure 2, the signifi-
cance was not observed among SLIT-receiving pa-
tients unfortunately, suggesting other factors influ-
ence the severity of clinical symptoms, and we need
further investigation.
We then investigated the grade of IL-10 production
in non-allergic healthy controls. As shown in Figure
3, the percentages of IL-10 producing monocyte and
CD4 T cells were significantly elevated in Cry j1- and
Cry j2-stimulated PBMC from normal healthy con-
trols compared to those from patients with pollinosis.
In addition, abundant IL-10 production was recog-
nized even when PBMC were stimulated with control
antigens such as tetanus toxoid or PPD. In addition to
allergen specific suppressive effect, IL-10 may have
broad potential in the immune modulations.
This study demonstrated that IL-10 is critical for in-
duction of specific T cell tolerance, and that the in-
creased production of IL-10 by monocytes and T cells
may affect to effector cells during inflammatory re-
sponses to allergen or after therapy with SIT. These
observations suggest that low production of IL-10 by
monocytes and T cells may play a critical role in the
initiation of allergic responses.
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